{"filing":{"accession_number":"0001827635-26-000023","cik":"0001827635","ticker":"MANE","company_name":"Veradermics, Inc","form":"8-K","filing_date":"2026-07-15","report_date":null,"primary_document":"mane-20260715.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1827635/000182763526000023/mane-20260715.htm"},"events":[{"id":18035,"run_id":16190,"accession_number":"0001827635-26-000023","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Veradermics announced positive Phase 2 clinical trial results for VDPHL01 in female pattern hair loss, demonstrating efficacy (88.9–90.0% of patients reporting improvement at Month 6) with rapid onset and a favorable safety profile including no treatment-related serious adverse events. This material clinical milestone supports advancement toward the Phase 2/3 registration trial (Study '306') with topline data anticipated in 1H 2027.","company_name":"Veradermics, Inc","ticker":"MANE","filing_date":"2026-07-15","form":"8-K","submitted_at":null,"items":[{"id":16728,"accession_number":"0001827635-26-000023","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Veradermics announced positive Phase 2 clinical trial results for VDPHL01 in female pattern hair loss, demonstrating efficacy (88.9–90.0% of patients reporting improvement at Month 6) and a favorable safety profile. This is a material operational/clinical milestone for a late-stage biopharmaceutical company whose lead program is VDPHL01; the data strengthen conviction ahead of the pivotal Phase 2/3 Study '306' readout anticipated in 1H 2027. While not a traditional earnings release, restatement, or M\u0026A event, the positive clinical proof-of-concept is material to investors assessing the company's regulatory and commercial prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-15T12:55:48.721098+00:00","company_name":"","ticker":null,"filing_date":""},{"id":16729,"accession_number":"0001827635-26-000023","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Veradermics announced positive Phase 2 clinical trial results for VDPHL01 in female pattern hair loss, demonstrating rapid onset of hair growth, consistent efficacy (88.9–90.0% of participants achieving 'improved' or 'much improved' outcomes), and a favorable safety profile with no treatment-related serious adverse events. This is a material clinical milestone for a late-stage biopharmaceutical company's lead product candidate, supporting advancement toward a Phase 2/3 registration trial (Study '306') with topline data anticipated in 1H 2027. While not a formal earnings release, M\u0026A activity, or governance event, this clinical success is a significant operational and strategic development that would affect a reasonable investor's assessment of the company's prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-15T12:55:48.721098+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":16728,"accession_number":"0001827635-26-000023","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Veradermics announced positive Phase 2 clinical trial results for VDPHL01 in female pattern hair loss, demonstrating efficacy (88.9–90.0% of patients reporting improvement at Month 6) and a favorable safety profile. This is a material operational/clinical milestone for a late-stage biopharmaceutical company whose lead program is VDPHL01; the data strengthen conviction ahead of the pivotal Phase 2/3 Study '306' readout anticipated in 1H 2027. While not a traditional earnings release, restatement, or M\u0026A event, the positive clinical proof-of-concept is material to investors assessing the company's regulatory and commercial prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-15T12:55:48.721098+00:00","company_name":"Veradermics, Inc","ticker":"MANE","filing_date":"2026-07-15"},{"id":16729,"accession_number":"0001827635-26-000023","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Veradermics announced positive Phase 2 clinical trial results for VDPHL01 in female pattern hair loss, demonstrating rapid onset of hair growth, consistent efficacy (88.9–90.0% of participants achieving 'improved' or 'much improved' outcomes), and a favorable safety profile with no treatment-related serious adverse events. This is a material clinical milestone for a late-stage biopharmaceutical company's lead product candidate, supporting advancement toward a Phase 2/3 registration trial (Study '306') with topline data anticipated in 1H 2027. While not a formal earnings release, M\u0026A activity, or governance event, this clinical success is a significant operational and strategic development that would affect a reasonable investor's assessment of the company's prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-15T12:55:48.721098+00:00","company_name":"Veradermics, Inc","ticker":"MANE","filing_date":"2026-07-15"}]}